Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib‐based regimens

Ibrutinib is active in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). In patients treated with ibrutinib for R/R CLL, del(17p), identified by interphase fluorescence in situ hybridization (FISH), is associated with inferior progression‐free survival despite equivalent initial response rates. Del(17p) is frequently associated with a complex metaphase karyotype (CKT); the prognostic significance of CKT in ibrutinib‐treated patients has not been reported.

[1]  Susan O'Brien,et al.  Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. , 2015, Blood.

[2]  A. Rosenwald,et al.  Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. , 2014, The Lancet. Oncology.

[3]  J. Byrd,et al.  Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. , 2014, The New England journal of medicine.

[4]  Jeffrey A Jones,et al.  Independent evaluation of ibrutinib efficacy 3 years post-initiation of monotherapy in patients with chronic lymphocytic leukemia/small lymphocytic leukemia including deletion 17p disease. , 2014 .

[5]  J. Friedberg,et al.  Ibrutinib In Combination With Bendamustine and Rituximab Is Active and Tolerable In Patients With Relapsed/Refractory CLL/SLL: Final Results Of a Phase 1b Study , 2013 .

[6]  Juthamas Sukbuntherng,et al.  Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. , 2013, The New England journal of medicine.

[7]  Jeffrey A Jones,et al.  Complex karyotype predicts for inferior outcomes following reduced‐intensity conditioning allogeneic transplant for chronic lymphocytic leukaemia , 2012, British journal of haematology.

[8]  M. Grever,et al.  Outcome of patients with relapsed or refractory chronic lymphocytic leukemia treated with flavopiridol: impact of genetic features , 2012, Leukemia.

[9]  C. Bueso-Ramos,et al.  Nonmyeloablative allogeneic stem cell transplantation in relapsed/refractory chronic lymphocytic leukemia , 2011, Cancer.

[10]  Jeffrey A Jones,et al.  Enhanced detection of chromosomal abnormalities in chronic lymphocytic leukemia by conventional cytogenetics using CpG oligonucleotide in combination with pokeweed mitogen and phorbol myristate acetate. , 2011, Cancer genetics.

[11]  N. Schmitz,et al.  Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. , 2010, Blood.

[12]  A. Berrebi,et al.  Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial , 2010, The Lancet.

[13]  N. Schmitz,et al.  Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  J. Radich,et al.  Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  T. Haferlach,et al.  Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgVH status and immunophenotyping , 2007, Leukemia.

[16]  T. Haferlach,et al.  Immunostimulatory oligonucleotide-induced metaphase cytogenetics detect chromosomal aberrations in 80% of CLL patients: A study of 132 CLL cases with correlation to FISH, IgVH status, and CD38 expression. , 2006, Blood.

[17]  D. Oscier,et al.  Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. , 2002, Blood.

[18]  H. Döhner,et al.  Comparative genomic hybridization in chronic B-cell leukemias shows a high incidence of chromosomal gains and losses. , 1995, Blood.

[19]  Eric R. Ziegel,et al.  Analysis of Binary Data (2nd ed.) , 1991 .

[20]  S. Knuutila,et al.  Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. , 1990, The New England journal of medicine.

[21]  F. Lanza,et al.  Cytogenetic aspects of B-cell chronic lymphocytic leukemia: their correlation with clinical stage and different polyclonal mitogens. , 1987, Cancer genetics and cytogenetics.

[22]  M. Pike,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.

[23]  D. Cox,et al.  The analysis of binary data , 1971 .

[24]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[25]  L. Zech,et al.  Prognostic information from cytogenetic analysis in chronic B-lymphocytic leukemia and leukemic immunocytoma. , 1985, Blood.

[26]  Iscn.  International System for Human Cytogenetic Nomenclature , 1978 .